1. Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction.
- Author
-
Li J, Sun S, Zhu D, Mei X, Lyu Y, Huang K, Li Y, Liu S, Wang Z, Hu S, Lutz HJ, Popowski KD, Dinh PC, Butte AJ, and Cheng K
- Subjects
- Animals, Mice, Administration, Inhalation, Disease Models, Animal, Swine, Myocytes, Cardiac metabolism, Myocytes, Cardiac pathology, Male, Ventricular Function, Left, Humans, Myocardium metabolism, Myocardium pathology, Stem Cells metabolism, CD36 Antigens metabolism, CD36 Antigens genetics, Myocardial Infarction metabolism, Myocardial Infarction pathology, Myocardial Infarction therapy, Myocardial Infarction physiopathology, Exosomes metabolism, Mice, Inbred C57BL
- Abstract
Background: Exosome therapy shows potential for cardiac repair after injury. However, intrinsic challenges such as short half-life and lack of clear targets hinder the clinical feasibility. Here, we report a noninvasive and repeatable method for exosome delivery through inhalation after myocardial infarction (MI), which we called stem cell-derived exosome nebulization therapy (SCENT)., Methods: Stem cell-derived exosomes were characterized for size distribution and surface markers. C57BL/6 mice with MI model received exosome inhalation treatment through a nebulizer for 7 consecutive days. Echocardiographies were performed to monitor cardiac function after SCENT, and histological analysis helped with the investigation of myocardial repair. Single-cell RNA sequencing of the whole heart was performed to explore the mechanism of action by SCENT. Last, the feasibility, efficacy, and general safety of SCENT were demonstrated in a swine model of MI, facilitated by 3-dimensional cardiac magnetic resonance imaging., Results: Recruitment of exosomes to the ischemic heart after SCENT was detected by ex vivo IVIS imaging and fluorescence microscopy. In a mouse model of MI, SCENT ameliorated cardiac repair by improving left ventricular function, reducing fibrotic tissue, and promoting cardiomyocyte proliferation. Mechanistic studies using single-cell RNA sequencing of mouse heart after SCENT revealed a downregulation of Cd36 in endothelial cells (ECs). In an EC- Cd36
fl/- conditional knockout mouse model, the inhibition of CD36, a fatty acid transporter in ECs, led to a compensatory increase in glucose utilization in the heart and higher ATP generation, which enhanced cardiac contractility. In pigs, cardiac magnetic resonance imaging showed an enhanced ejection fraction (Δ=11.66±5.12%) and fractional shortening (Δ=5.72±2.29%) at day 28 after MI by SCENT treatment compared with controls, along with reduced infarct size and thickened ventricular wall., Conclusions: In both rodent and swine models, our data proved the feasibility, efficacy, and general safety of SCENT treatment against acute MI injury, laying the groundwork for clinical investigation. Moreover, the EC- Cd36fl/- mouse model provides the first in vivo evidence showing that conditional EC-CD36 knockout can ameliorate cardiac injury. Our study introduces a noninvasive treatment option for heart disease and identifies new potential therapeutic targets., Competing Interests: Dr Li is currently an employee of Xsome Biotech Inc. Dr Cheng is a cofounder and equity holder of Xsome Biotech Inc. The remaining authors report no conflicts.- Published
- 2024
- Full Text
- View/download PDF